The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial
Open accessAbstract
INTRODUCTION: Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently accelerates gastric emptying. Dyspepsia and gastroparesis are common problems in type 1 diabetes mellitus. We aimed to evaluate the efficacy of ABT-229 in symptomatic diabetic patients with and without delayed gastric emptying. METHODS: Patients with type 1 diabetes and postprandial symptoms were randomised (n=270). Based on a validated C 13 octanoic acid breath test, patients were assigned to either the delayed or normal gastric emptying strata. Patients received one of four doses of ABT-229 (1.25, 2.5, 5, or 10 mg twice daily before breakfast and dinner) or placebo for four weeks following a two week baseline. A self report questionnaire measured symptoms on visual analogue scales; the primary outcome was assessment of change in the total upper abdominal symptom severity score (range 0–800 mm) from baseline to the final visit. RESULTS: The treatment arms were similar regarding baseline characteristics. There was symptom improvement on placebo and a similar level of improvement on active therapy for the upper abdominal discomfort severity score (mean change from baseline −169, −101, −155, −143, and −138 mm for placebo, and 1.25, 2.5, 5, and 10 mg ABT-229, respectively, at four weeks by intent to treat). The results were not significantly different in those with and without delayed gastric emptying. The severity of bloating, postprandial nausea, epigastric discomfort, heartburn, and acid regurgitation worsened dose dependently in a greater number of patients receiving ABT-229 than placebo. Overall, 63% of patients on placebo reported a good or excellent global response, and this was not different from the active treatment arms. CONCLUSIONS: The motilin agonist ABT-229 was not efficacious in the relief of postprandial symptoms in diabetes mellitus in the presence or absence of delayed gastric emptying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disorders of gastrointestinal motility associated with diabetes mellitus
FELDMAN, M., & SCHILLER, L. R. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-3-378 · Cited by 653
Gastric emptying in diabetes mellitus: relationship to blood-glucose control
Kong, M.-F., & Horowitz, M. (1999) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30062-4 · Cited by 80
Cited by
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738
Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000021689.86296.e4 · Cited by 418
Self-citationRevicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01612.x · Cited by 383
Self-citationARTS, J., HOLVOET, L., CAENEPEEL, P., BISSCHOPS, R., SIFRIM, D., VERBEKE, K., JANSSENS, J., & TACK, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03467.x · Cited by 368
Abell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361
Self-citationMurray, C. D. R., Martin, N. M., Patterson, M., Taylor, S. A., Ghatei, M. A., Kamm, M. A., Johnston, C., Bloom, S. R., & Emmanuel, A. V. (2005) · Gut · doi:10.1136/gut.2005.069088 · Cited by 322
Gastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308
Janssen, P., Harris, S. M., Jones, M., Masaoka, T., Farré, R., Törnblom, H., Van Oudenhove, L., Simrén, M., & Tack, J. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.118 · Cited by 260
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Diabetic gastropathy and prokinetics
Talley, N. J. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07268.x · Cited by 81
Self-citationDifferent faces of gastroparesis
Bielefeldt, K., Raza, N., & Zickmund, S. L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.6052 · Cited by 71
Functional dyspepsia and gastroparesis: one disease or two
Lacy, B. E. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.104 · Cited by 66
Tack, J. (2007) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2007.04.001 · Cited by 63
Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis
Ingrosso, M. R., Camilleri, M., Tack, J., Ianiro, G., Black, C. J., & Ford, A. C. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.12.014 · Cited by 53
Petri, M., Singh, I., Baker, C., Underkofler, C., & Rasouli, N. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107733 · Cited by 50
Shin, A. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00231-0 · Cited by 30
Time trends in gastroparesis treatment
Dudekula, A., Rahim, S., & Bielefeldt, K. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3369-y · Cited by 21
Metadata
- Authors
- Talley, N. J., Verlinden, M., Geenen, D. J., Hogan, R. B., Riff, D., McCallum, R. W., & Mack, R. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-09-01
- Volume
- 49
- Issue
- 3
- Pages
- 395-401
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2164085009
- Cited by
- 161
- References
- 2
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.